FDA Temporarily Suspends Banning Order On Juul’s E-Cigarettes
The FDA temporarily suspended its ban on sales of the popular e-cigarette maker Juul, backed by Altria Group Inc
‘X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom’s Macroglobulinemia’ -TradeHawk, Citing FDA Site
https://twitter.com/TradeHawk/status/1542897334085775360
‘WSJ News Exclusive | FDA Planning to Allow Clinical Trials of Pig Organ Transplants’ – WSJ
https://www.wsj.com/articles/fda-said-to-plan-pig-organ-transplant-clinical-trials-11656622411
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922
NRx Pharmaceuticals Announces FDA Declines Emergency Use Authorization For ZYESAMI For Subgroup Of Patients With Critical COVID-19 At Immediate Risk Of Death From Respiratory Failure Despite Treatment With Approved Therapy, Including Remdesivir
Focus is now on NRX-101 for Bipolar Depression with Suicidality
RADNOR, Pa., July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals"), a clinical-stage
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.